vs
Castellum, Inc.（CTM）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Castellum, Inc.的1.6倍（$19.6M vs $12.6M），Castellum, Inc.净利率更高（-10.5% vs -177.4%，领先166.9%），Castellum, Inc.同比增速更快（21.9% vs -11.5%），过去两年Castellum, Inc.的营收复合增速更高（5.3% vs -12.2%）
Castellum, Inc.是一家总部位于美国的网络安全与信息技术服务提供商，服务覆盖国防政府机构、公共部门及商业企业客户，提供威胁检测、数据保护、云安全及托管IT解决方案，助力客户防范网络风险、保护核心数字资产。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CTM vs LAB — 直观对比
营收规模更大
LAB
是对方的1.6倍
$12.6M
营收增速更快
CTM
高出33.4%
-11.5%
净利率更高
CTM
高出166.9%
-177.4%
两年增速更快
CTM
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.6M | $19.6M |
| 净利润 | $-1.3M | $-34.7M |
| 毛利率 | 33.9% | 48.5% |
| 营业利润率 | -11.1% | -168.5% |
| 净利率 | -10.5% | -177.4% |
| 营收同比 | 21.9% | -11.5% |
| 净利润同比 | 51.8% | -28.8% |
| 每股收益（稀释后） | $-0.02 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMLAB
| Q4 25 | $12.6M | — | ||
| Q3 25 | $14.6M | $19.6M | ||
| Q2 25 | $14.0M | $21.8M | ||
| Q1 25 | $11.7M | $40.8M | ||
| Q4 24 | $10.3M | — | ||
| Q3 24 | $11.6M | $22.1M | ||
| Q2 24 | $11.5M | $22.5M | ||
| Q1 24 | $11.3M | $45.5M |
净利润CTMLAB
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $415.4K | $-34.7M | ||
| Q2 25 | $-322.1K | $-33.5M | ||
| Q1 25 | $-1.2M | $-26.0M | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-1.3M | $-26.9M | ||
| Q2 24 | $-1.8M | $-45.7M | ||
| Q1 24 | $-4.1M | $-32.2M |
毛利率CTMLAB
| Q4 25 | 33.9% | — | ||
| Q3 25 | 37.6% | 48.5% | ||
| Q2 25 | 36.1% | 48.8% | ||
| Q1 25 | 39.0% | 48.4% | ||
| Q4 24 | 40.0% | — | ||
| Q3 24 | 42.7% | 54.9% | ||
| Q2 24 | 40.6% | 46.1% | ||
| Q1 24 | 39.8% | 53.1% |
营业利润率CTMLAB
| Q4 25 | -11.1% | — | ||
| Q3 25 | 3.0% | -168.5% | ||
| Q2 25 | -2.7% | -118.1% | ||
| Q1 25 | -12.7% | -80.8% | ||
| Q4 24 | -15.7% | — | ||
| Q3 24 | -11.9% | -120.9% | ||
| Q2 24 | -13.6% | -134.5% | ||
| Q1 24 | -23.6% | -132.2% |
净利率CTMLAB
| Q4 25 | -10.5% | — | ||
| Q3 25 | 2.8% | -177.4% | ||
| Q2 25 | -2.3% | -153.7% | ||
| Q1 25 | -10.0% | -63.8% | ||
| Q4 24 | -26.6% | — | ||
| Q3 24 | -11.0% | -122.0% | ||
| Q2 24 | -16.0% | -203.3% | ||
| Q1 24 | -36.3% | -70.6% |
每股收益（稀释后）CTMLAB
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $0.00 | $-0.09 | ||
| Q2 25 | $0.00 | $-0.09 | ||
| Q1 25 | $-0.01 | $-0.07 | ||
| Q4 24 | $-0.05 | — | ||
| Q3 24 | $-0.02 | $-0.07 | ||
| Q2 24 | $-0.03 | $-0.12 | ||
| Q1 24 | $-0.08 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $35.8M | $399.7M |
| 总资产 | $41.9M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $129.4M | ||
| Q2 25 | — | $158.6M | ||
| Q1 25 | — | $150.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M |
总债务CTMLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.0M | — | ||
| Q3 24 | $8.3M | $55.2M | ||
| Q2 24 | $8.7M | $55.1M | ||
| Q1 24 | $9.0M | $55.0M |
股东权益CTMLAB
| Q4 25 | $35.8M | — | ||
| Q3 25 | $36.7M | $399.7M | ||
| Q2 25 | $31.8M | $424.5M | ||
| Q1 25 | $26.1M | $454.6M | ||
| Q4 24 | $20.2M | — | ||
| Q3 24 | $12.0M | $489.3M | ||
| Q2 24 | $12.1M | $510.3M | ||
| Q1 24 | $12.8M | $577.3M |
总资产CTMLAB
| Q4 25 | $41.9M | — | ||
| Q3 25 | $46.3M | $539.6M | ||
| Q2 25 | $43.4M | $557.0M | ||
| Q1 25 | $41.1M | $579.6M | ||
| Q4 24 | $37.8M | — | ||
| Q3 24 | $28.8M | $681.5M | ||
| Q2 24 | $29.5M | $708.7M | ||
| Q1 24 | $30.5M | $777.7M |
负债/权益比CTMLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 0.69× | 0.11× | ||
| Q2 24 | 0.72× | 0.11× | ||
| Q1 24 | 0.70× | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-661.7K | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CTMLAB
| Q4 25 | $-661.7K | — | ||
| Q3 25 | $1.0M | $-22.2M | ||
| Q2 25 | $214.2K | $-20.7M | ||
| Q1 25 | $-2.5M | $-30.3M | ||
| Q4 24 | $-394.4K | — | ||
| Q3 24 | $742.2K | $-27.9M | ||
| Q2 24 | $748.6K | $-39.0M | ||
| Q1 24 | $23.7K | $-62.5M |
自由现金流CTMLAB
| Q4 25 | — | — | ||
| Q3 25 | $957.0K | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $738.9K | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率CTMLAB
| Q4 25 | — | — | ||
| Q3 25 | 6.5% | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.4% | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度CTMLAB
| Q4 25 | — | — | ||
| Q3 25 | 0.3% | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 10.2% | ||
| Q2 24 | 0.0% | 8.6% | ||
| Q1 24 | 0.0% | 1.7% |
现金转化率CTMLAB
| Q4 25 | — | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTM
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
